Conflict of interest None declared.
Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis
Article first published online: 9 NOV 2010
© 2010 The Authors. Journal compilation © 2010 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 24, Issue 12, pages 1447–1451, December 2010
How to Cite
Akhyani, M., Chams-Davatchi, C., Hemami, M. and Fateh, S. (2010), Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 24: 1447–1451. doi: 10.1111/j.1468-3083.2010.03667.x
- Issue published online: 9 NOV 2010
- Article first published online: 9 NOV 2010
- Received: 1 November 2009; Accepted: 25 February 2010
- mycophenolate mofetil;
Background Methotrexate (MTX) is a well-known systemic drug for moderate to severe chronic plaque psoriasis. Recently, mycophenolate mofetil (MMF) has been recommended for psoriasis.
Objective To compare the efficacy and safety of MMF vs. MTX for the treatment of chronic plaque psoriasis.
Methods Thirty-eight consecutive patients with Psoriasis Area and Severity Index (PASI) >10 were randomly assigned for 12 weeks of treatment with either MTX (18 patients; initial dose, 7.5 mg/week) or MMF (20 patients; dose; 2 g/day) and were followed for 12 weeks after discontinuing the treatment. The differences between the two groups were analysed at the end of treatment and follow-up comparing with baseline values.
Results After 12 weeks of treatment, the mean ± SD score for the PASI decreased from 16.46 ± 5.29 at baseline to 3.17 ± 2.35 among 15 patients treated with MTX, whereas the score decreased from 17.43 ± 7.42 to 3.97 ± 5.95 among 17 patients treated with MMF (P > 0.05). Twelve weeks after discontinuing the treatment, the scores were 4.77 ± 3.52 and 5.94 ± 4.27, respectively (P > 0.05). PASI -75 were achieved in 58.8% of patients in MMF group and 73.3% in MTX group (P > 0.05). Three months after discontinuing the treatment, PASI-75 remained in 33.3% of patients in MMF and 53.3% of MTX group (P > 0.05). Both drugs were well tolerated and side-effects were minor and transient.
Conclusions No significant differences in efficacy were found between MTX and MMF groups. MMF may represent a good alternative for the treatment of psoriasis in patients who are unable to take MTX or other available drugs due to contraindication or toxicity.